Walker, A. J. and Card, T. and Bates, T. E. and Muir, K. (2011) Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. British Journal of Cancer, 104 (1). pp. 193-197. ISSN 0007-0920
Full content URL: http://www.nature.com/bjc/journal/v104/n1/abs/6605...
Full text not available from this repository.
Background: Several studies suggest links between cancer and tricyclic antidepressant use.
Methods: A case–control study using the General Practice Research Database examined whether previous tricyclic usage was associated with reduced incidence of brain (with glioma as a sub-category), breast, colorectal, lung and prostate cancers. Conditional logistic regression adjusted for age, gender, general practice, depression, smoking, body mass index, alcohol use and non-steroidal anti-inflammatory drug use.
Results: A total of 31 953 cancers were identified, each matched with up to two controls. We found a statistically significant reduction in tricyclic prescriptions compared with controls in glioma (odds ratio (OR) =0.59, 95% confidence interval (CI)=0.42–0.81) and colorectal cancer patients (OR=0.84, CI=0.75–0.94). These effects were dose-dependent (P-values for trend, glioma=0.0005, colorectal=0.001) and time-dependant (P-values for trend glioma=0.0005, colorectal=0.0086). The effects were cancer-type specific, with lung, breast and prostate cancers largely unaffected by antidepressant use.
Conclusion: The biologically plausible, specific and dose- and time-dependant inverse association that we have found suggests that tricyclics may have potential for prevention of both colorectal cancer and glioma.
|Keywords:||tricyclic antidepressants, glioma, colorectal cancer, GPRD|
|Subjects:||C Biological Sciences > C720 Biological Chemistry|
|Divisions:||College of Science > School of Life Sciences|
|Deposited By:||Alison Wilson|
|Deposited On:||04 Mar 2011 09:44|
|Last Modified:||29 Nov 2013 09:32|
Repository Staff Only: item control page